ALX Oncology Brings In Experienced Oncology Executive Jeff Knight To Lead Development And Operational Strategy

ALX Oncology Holdings Inc. announced that Jeff Knight, M.P.H., has been appointed as the company’s new Chief Development and Operating Officer, effective April 13, 2026. ALX Oncology is a clinical-stage biotechnology company focused on advancing novel cancer therapies with the goal of improving and extending patients’ lives.

Chief Executive Officer Jason Lettmann stated that Knight is a highly accomplished leader with extensive experience in clinical development and operations. He noted that Knight has a proven ability to guide innovative therapies through key stages of growth, including late-stage development and preparation for commercialization. Lettmann also emphasized that the company expects several important milestones in the next 12 to 18 months as it continues to progress its evorpacept and ALX2004 clinical programs. He added that Knight’s leadership will help strengthen ALX Oncology’s development capabilities and operational foundation to support the successful execution of these upcoming milestones.

Jeff Knight brings more than three decades of experience in the biopharmaceutical industry. Throughout his career, he has played a major role in advancing programs from early research stages through clinical development and ultimately to commercialization, with significant experience in oncology. Most recently, he served as Chief Development and Operating Officer at Crinetics Pharmaceuticals, where he oversaw clinical development, portfolio strategy, and overall corporate operations.

Before his tenure at Crinetics, Knight held senior leadership positions at Poseida Therapeutics, Halozyme Therapeutics, Amgen, and Onyx Pharmaceuticals. In these roles, he led a wide range of development and operational functions, supporting the advancement of multiple therapeutic programs. Earlier in his career, he worked at Genentech, where he gained strong experience in oncology clinical development and regulatory affairs.

Knight said he is excited to join ALX Oncology at a pivotal moment for the company. He noted that the organization is entering an important phase of growth, with significant opportunities to advance its pipeline and build a scalable operational structure. He expressed enthusiasm about the company’s clinical data and programs and looks forward to contributing to strategic development and strong operational execution as ALX Oncology approaches key clinical and corporate milestones. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma. He also holds a Bachelor of Science in Nursing from the University of Kansas.